Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

Cited by (387)

Items 201–300 of 387

1. The potential of sunitinib as a therapy in ovarian cancer
   Umberto Leone Roberti Maggiore, Mario Valenzano Menada, Pier Luigi Venturini · 2013 · Expert Opinion on Investigational Drugs
2. Review: Targeted therapy in renal cancer
   Tanya Barauskas Dorff, Amir Goldkorn, David I. Quinn · 2009 · Therapeutic Advances in Medical Oncology
3. Cancer
   William C. Hahn · 2004 · Cancer Cell
4. Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma
   Lauren C. Harshman, Calvin Jay Kuo, Bryan Y. Wong · 2009 · Cancer Investigation
5. Targeted therapies for patients with germ cell tumors
   Martin H Fenner, Gernot Beutel, Viktor Grünwald · 2008 · Expert Opinion on Investigational Drugs
6. Genotype and Phenotype Landscape of 283 Japanese Patients with Tuberous Sclerosis Complex
   Sumihito Togi, Hiroki Ura, Hisayo Hatanaka, Yo Niida · 2022 · International Journal of Molecular Sciences
7. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
   Dominik Paul Modest, Peter Čamaj, Volker Heinemann, B. Schwarz, Andreas Jung, Rüdiger Paul Laubender, Sebastian Gamba, Christoph Haertl, Sebastian Stintzing, S. Primo et al. · 2013 · Journal of Cancer Research and Clinical Oncology
8. Combined anti-proliferative and anti-angiogenic strategies for cancer
   Jair Bar, Amir Onn · 2008 · Expert Opinion on Pharmacotherapy
9. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
   Epie Boven, Christophe Massard, Jean‐Pierre Armand · 2010 · British Journal of Cancer
10. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
    Attila Kollár, Marco Maruzzo, Christina Messiou et al. · 2014 · Clinical Sarcoma Research
11. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma
    Kana Iwamoto, Hiroki Ishihara, Toshio Takagi · 2018 · Medical Oncology
12. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain
    Emiliano Calvo, Pablo Maroto, Noémi Kreif · 2011 · Clinical & Translational Oncology
13. The potential role of sunitinib targeting melanomas
    Matias Emanuel Valsecchi, Takami Sato · 2013 · Expert Opinion on Investigational Drugs
14. BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells
    Hye‐Eun Choi, Min‐Sang Yoo, Jung‐Hye Choi et al. · 2011 · Bioorganic & Medicinal Chemistry Letters
15. Anti-Angiogenic Treatment of Gastrointestinal Malignancies
    J. Stuart Salmon, Albert Craig Lockhart, Jordan D. Berlin · 2005 · Cancer Investigation
16. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation
    Feng Pan, Jing Tian, Xu‐Chao Zhang, Ying Zhang, Yueyin Pan · 2011 · Journal of Cancer Research and Clinical Oncology
17. Novel Therapies for the Treatment of Small-Cell Lung Cancer
    Ruth E Board, Nick Thatcher, Paul C. Lorigan · 2006 · Drugs
18. The effect of adenosine triphosphate on sunitinib-induced cardiac injury in rats
    MN Aldemir, Melih Şimşek, AV Kara · 2020 · Human & Experimental Toxicology
19. Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez‐Estévez, Luis León‐Mateos, Ovidio Fernández · 2012 · Advances in Therapy
20. Implications of Mutational Analysis for the Management of Patients With Gastrointestinal Stromal Tumors and the Application of Targeted Therapies
    Agnieszka Woźniak, Giuseppe Floris, Maria Dêbiec‐Rychter · 2010 · Cancer Investigation
21. Constitutively active α subunits of Gq/11 and G12/13 families inhibit activation of the pro‐survival Akt signaling cascade
    Eddy H.T. Wu, Becky H. L. Tam, Yung Hou Wong · 2006 · FEBS Journal
22. An HPLC Method for Simultaneous Quantification of Sunitinib and its Active Metabolite, Su12662, Using Hydrophilic Interaction Chromatography Principle
    Murari Gurjar, Parsshava Mehta, Jyoti Sharma · 2020 · Bioanalysis
23. Molecular mechanisms underlying hepatitis C virus infection-related diabetes
    Yujin Ding, Guangdi Li, Zhiguang Zhou, Tuo Deng · 2021 · Metabolism
24. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer
    Carlos Gómez-Martín, Ramón Salazar, Clara O. Montagut et al. · 2012 · Investigational New Drugs
25. Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
    Baskaran Govindarajan, Laura Willoughby, Hamid Band · 2012 · Vascular Cell
26. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer
    Narikazu Boku, Kei Muro, Nozomu Machida, Satoshi Hashigaki, Nobuyuki Kimura, Mie Suzuki, Mariajosé Lechuga, Yoshinori Miyata · 2013 · Investigational New Drugs
27. Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation
    Fuchun Yang, Shaogang Sun, Chenran Wang, Michael Haas, Syn Kok Yeo, Jun‐Lin Guan · 2020 · British Journal of Cancer
28. Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase
    Nimer Mehyar, Abdullah Mashhour, Imadul Islam, Sheraz Gul, Adeyemi O. Adedeji, Ahmed S. Al Askar, Mohamed Boudjelal · 2021 · SAR and QSAR in environmental research
29. Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors
    Maddalena Centanni, Sreenath M. Krishnan, Lena E. Friberg · 2020 · Clinical Cancer Research
30. Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug–drug interaction assessment in a mouse model
    Jian Ren Tan, Srikumar Chakravarthi, John Paul Judson, Nagaraja Haleagrahara, Ignacio Segarra · 2013 · Naunyn-Schmiedeberg s Archives of Pharmacology
31. Targeted therapies in small-cell lung cancer
    Khaled Fernainy, Nabil F. Saba · 2007 · Expert Opinion on Therapeutic Targets
32. Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models
    Lin Yu, Yuqin Yao, Yuxi Wang et al. · 2018 · Journal of drug targeting
33. Irradiation exacerbates cortical cytopathology in the Eker rat model of tuberous sclerosis complex, but does not induce hyperexcitability
    Naranzogt Tschuluun, H. Jürgen Wenzel, Philip A. Schwartzkroin · 2006 · Epilepsy Research
34. Assays for membrane tyrosine kinase receptors: methods for high-throughput screening and utility for diagnostics
    Lisa K. Minor · 2005 · Expert Review of Molecular Diagnostics
35. Proliferative, degradative smooth muscle cells promote aortic disease
    Maarten Hulsmans, Matthias Nahrendorf · 2020 · Journal of Clinical Investigation
36. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma
    D. Ross Camidge, Normand Blais, Derek J. Jonker et al. · 2012 · Cancer Chemotherapy and Pharmacology
37. Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population
    Ping Gu, Huimin Wang, Wang Wei-Min · 2010 · Medical Oncology
38. Tuberous sclerosis complex
    Finbar J. O'Callaghan · 2008 · Paediatrics and Child Health
39. A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma
    Kezban Nur Pilanc, Filiz Elbüken, Çetın Ordu · 2014 · American Journal of Therapeutics
40. Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management
    Pascal Wolter, Patrick Schöffski · 2009 · Acta Oncologica
41. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
    Elisabeth I. Heath, George R. Blumenschein, Roger B. Cohen · 2010 · Cancer Chemotherapy and Pharmacology
42. Positron emission tomography methods with potential for increased understanding of mental retardation and developmental disabilities
    Senthil K. Sundaram, Harry T. Chugani, Diane C. Chugani · 2005 · Mental Retardation and Developmental Disabilities Research Reviews
43. Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies
    Andrew Mark Scott, Paul L R Mitchell, Graeme Joseph O'Keefe · 2012 · EJNMMI Research
44. Sunitinib for the treatment of thyroid cancer
    José-Manuel Gómez-Sáez · 2016 · Expert Opinion on Investigational Drugs
45. The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor
    Peng Liu, Fengbo Tan, Heli Liu · 2020 · OncoTargets and Therapy
46. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit)
    Emad Y. Moawad · 2015 · Journal of Gastrointestinal Cancer
47. Emerging drugs to replace current leaders in first-line therapy for breast cancer
    Michael Craig Cox, Tu Dan, Sandra M. Swain · 2006 · Expert Opinion on Emerging Drugs
48. Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
    Halıt Karaca, Ayhan Lale, Mustafa Dikilitaş · 2009 · Medical Oncology
49. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
    Laura Q.M. Chow, Normand Blais, Derek J. Jonker et al. · 2011 · Cancer Chemotherapy and Pharmacology
50. Update on new drugs in small cell lung cancer
    Leora Horn, Emily Louise Castellanos, David H. Johnson · 2011 · Expert Opinion on Investigational Drugs
51. LKB1 mutations and their correlation with LKB1 and Rheb expression in bladder cancer
    Hatice Tigli, Didem Seven, Murat Tunç, Öner Şanlı, Şerife Başaran, Turgut Ulutin, Nur Buyru · 2012 · Molecular Carcinogenesis
52. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma
    Sergio Bracarda, Sylvie Négrier, Jochen Casper · 2017 · Expert Review of Anticancer Therapy
53. Epilepsy in a melanocyte-lineage mTOR hyperactivation mouse model: A novel epilepsy model
    Fei Yang, Ling-Li Yang, M. Wataya-Kaneda, Lanting Teng, I. Katayama · 2020 · PLoS ONE
54. Certain Diet and Lifestyle May Contribute to Islet β-cells Protection in Type-2 Diabetes via the Modulation of Cellular PI3K/AKT Pathway
    Kitagishi, Yasuko, Nakanishi, Atsuko, Minami, Akari, Asai, Yurina, Yasui, Mai, Iwaizako, Akiko, Suzuki, Miho, Ono, Yuna, Ogura, Yasunori, Matsuda, Satoru · 2014 · The Open Biochemistry Journal
55. Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation
    Natasha M. Fewkes, Aviva C. Krauss, Martin Guimond · 2010 · Blood
56. Nierenzellkarzinom 2008
    Christine G. Hammerschmied, B. Walter, A. Hartmann · 2008 · Der Pathologe
57. Anchor-based classification and type-C inhibitors for tyrosine kinases
    Kai‐Cheng Hsu, Tzu-Ying Sung, Chih-Ta Lin, Yi-Yuan Chiu, John T.-A. Hsu, Hui‐Chen Hung, Chung‐Ming Sun, Indrajeet J. Barve, Wenliang Chen, Wen-Chien Huang et al. · 2015 · Scientific Reports
58. Signal integration in the (m)TORC1 growth pathway
    Ramlaul, Kailash, Aylett, Christopher H. S. · 2018 · Frontiers in Biology
59. Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma
    Yoshinori Hoshino, Hirotoshi Hasegawa, Yoshiyuki Ishii et al. · 2011 · International Journal of Clinical Oncology
60. Tyrosine Kinase Inhibitors in Pediatric Malignancies
    Jeffrey M. Skolnik, Peter C. Adamson · 2007 · Cancer Investigation
61. Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes
    Viera Kútna, Valerie B. O’Leary, Ehren Lee Newman, Cyril Höschl, Saak Victor Ovsepian · 2021 · Neurotherapeutics
62. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer
    Paul Nguewa, Alfonso Calvo, Soni Savai Pullamsetti · 2010 · Expert Opinion on Investigational Drugs
63. Tsc2, a positional candidate gene underlying a quantitative trait locus for hepatic steatosis
    Chen‐Yu Wang, Donald S. Stapleton, Kathryn L. Schueler, Mary E. Rabaglia, Angie Tebon Oler, Mark P. Keller, Christina M. Kendziorski, Karl W. Broman, Brian S. Yandell, Eric E. Schadt et al. · 2012 · Journal of Lipid Research
64. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature
    Alia Fahmy, Ashley Mark Hopkins, Michael Joseph Sorich, Andrew Rowland · 2021 · Expert Opinion on Drug Metabolism & Toxicology
65. Role of novel targeted therapies in the clinic
    Roy S. Herbst · 2005 · British Journal of Cancer
66. Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
    Kiana Keyvanjah, Samuel E. DePrimo, Charles S. Harmon · 2012 · Journal of Translational Medicine
67. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients
    Gustavo Schvartsman, Michael J. Wagner, Chrystia M. Zobniw · 2016 · Current Oncology Reports
68. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
    Evelyn M. Mrozek, Vineeta Bajaj, Yanan Guo, Izabela A. Malinowska, Jianming Zhang, David J. Kwiatkowski · 2021 · PLoS ONE
69. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors
    Stephen Leong, Sabine Eckhardt, Emily W. Chan et al. · 2012 · Cancer Chemotherapy and Pharmacology
70. Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
    Anikó Maráz, Adrienne Cserháti, Gabriella Uhercsák · 2018 · BMC Cancer
71. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome
    Nienke A. G. Lankheet, Alwin D. R. Huitema, Henk A. Mallo · 2013 · European Journal of Clinical Pharmacology
72. Structure Activity Relationships of Quinoxalin-2-one Derivatives as Platelet-Derived Growth Factor-.BETA. Receptor (PDGF.BETA. R) Inhibitors, Derived from Molecular Modeling
    Yoshikazu Mori, Takatsugu Hirokawa, Katsuyuki Aoki · 2008 · Chemical and Pharmaceutical Bulletin
73. Longitudinal correspondence of epilepsy and scalp EEG fast (40–200 Hz) oscillations in pediatric patients with tuberous sclerosis complex
    Hiroki Tsuchiya, Fumika Endoh, Tomoyuki Akiyama · 2020 · Brain and Development
74. Genotype-phenotype correlation of patients with tuberous sclerosis complex–associated renal angiomyolipoma: a descriptive study
    Shuqiang Li, Yushi Zhang, Zhiyong Wang · 2018 · Human Pathology
75. Tuberous sclerosis complex: everything old is new again
    Kevin C. Ess · 2009 · Journal of Neurodevelopmental Disorders
76. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases
    Katsuhiro Makino, Kenji Yoda, Junzo Tomoishi · 2014 · BMC Research Notes
77. Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia
    Akane Tsujimura, Hitoshi Kiyoi, Yukimasa Shiotsu · 2010 · International Journal of Hematology
78. Lymphangioleiomyomatosis
    Francis X. McCormack, Eugene J. Sullivan, Yoshikazu Inoue · 2010 · Elsevier eBooks
79. Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro
    Susmita Ghosh, Mamatha Garige, P. Haggerty · 2024 · Cell Cycle
80. Acquired Cystic Disease-Associated Renal Cell Carcinoma: A Systematic Review and Meta-analysis
    Nguyen Xuong Duong, Minh‐Khang Le, Tuan Thanh Nguyen, Duy Duc Nguyen, Huy Gia Vuong, Tetsuo Kondo, Takahiko Mitsui · 2024 · Clinical Genitourinary Cancer
81. Advances in managing hepatocellular carcinoma
    Marielle Reataza, David K. Imagawa · 2014 · Frontiers of Medicine
82. The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma
    Francesca Romana Ponziani, Veronica Ojetti, Annalisa Tortora · 2011 · Expert Opinion on Drug Metabolism & Toxicology
83. Genetic defects in SAPK signalling, chromatin regulation, vesicle transport and CoA-related lipid metabolism are rescued by rapamycin in fission yeast
    Kenichi Sajiki, Yuria Tahara, Alejandro Villar‐Briones, Tomáš Pluskal, Takayuki Teruya, Ayaka Mori, Mitsuko Hatanaka, Masahiro Ebe, Takahiro Nakamura, Keita Aoki et al. · 2018 · Open Biology
84. Hydrocolloid dressing as a prophylactic use for hand–foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study
    Sadamoto Zenda, Asako Ryu, Atsuo Takashima et al. · 2020 · BMJ Open
85. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors
    Savita Bisht, Georg Feldmann, Peter Brossart · 2013 · Expert Opinion on Drug Metabolism & Toxicology
86. Therapy innovation for the treatment of pancreatic neuroendocrine tumors
    Ferdinando Riccardi, Mimma Rizzo, Lucia Festino, Francesca Ambrosio, Carlo Molino, Generoso Uomo, Giacomo Cartenì · 2012 · Expert Opinion on Therapeutic Targets
87. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
    Núria Laínez, Jesús García-Donás, Emilio Esteban, Javier Puente, M.I. Sáez, Enrique Gallardo, Álvaro Pinto-Marín, Sergio Vázquez‐Estévez, Luis León‐Mateos, Icíar García-Carbonero et al. · 2016 · BMC Cancer
88. Sunitinib
    Emma D. Deeks, Éric Raymond · 2011 · BioDrugs
89. Oral Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor Inhibitor Sunitinib Prevents Chronic Allograft Injury in Experimental Kidney Transplantation Model
    Jukka M. J. Rintala, Johanna Savikko, Niina Palin · 2015 · Transplantation
90. A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer
    Panagiotis Petrou · 2018 · Expert Review of Pharmacoeconomics & Outcomes Research
91. Forthcoming receptor tyrosine kinase inhibitors
    Nicholas W. Choong, Ezra E.W. Cohen · 2006 · Expert Opinion on Therapeutic Targets
92. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials
    Simge Acar, Amy E. Armstrong, Angela C. Hirbe · 2021 · Expert Opinion on Investigational Drugs
93. Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma
    Jorge Ayllon, Benoit Beuselinck, Alexandre Morel · 2011 · Cancer Investigation
94. The pharmacokinetic interaction between irinotecan and sunitinib
    Lili Jiang, Li Wang, Zhongmin Zhang · 2019 · Cancer Chemotherapy and Pharmacology
95. Advances in the treatment of gastrointestinal stromal tumor
    David R. D’Adamo · 2009 · Advances in Therapy
96. Future options for imatinib mesilate-resistant tumors
    Kamalesh Kumar Sankhala, Kyriakos P. Papadopoulos · 2007 · Expert Opinion on Investigational Drugs
97. Targeted Therapy for Renal Cell Carcinoma: A New Therapeutic Paradigm
    Philip E. Shaheen, Ronald M. Bukowski · 2006 · Cancer Investigation
98. Brief Report: S6 Ribosomal Protein Phosphorylation in Autistic Frontal Cortex and Cerebellum: a Tissue Array Analysis
    Charles G. Eberhart, Joshua A. Copeland, Ty William Abel · 2006 · Journal of Autism and Developmental Disorders
99. Emerging drugs for renal cell carcinoma
    Philip E. Shaheen, Ronald M. Bukowski · 2005 · Expert Opinion on Emerging Drugs
100. The Tuberous Sclerosis Complex
     Sergiusz Jóźwiak, Nicola Migone, Martino Ruggieri · 2008 · Springer eBooks